Biogen And Eisai Announce Japan Approval Of LEQEMBI Pen To Treat Early Alzheimer's Disease

Japan approved LEQEMBI Pen, a subcutaneous formulation of Biogen and Eisai's anti-amyloid beta protofibril antibody lecanemab. The approval adds a new administration route for LEQEMBI in Japan and is a modestly positive regulatory and commercialization development for both drugmakers.